European Commission Approves Merck’s KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults Read more
Lilly releases Zepbound (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Read more
Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH Read more
Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer Read more
GSK’s Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer Read more
Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070 Read more